These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 16842888)

  • 21. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone.
    Stewart VA; McGrath SM; Dubois PM; Pau MG; Mettens P; Shott J; Cobb M; Burge JR; Larson D; Ware LA; Demoitie MA; Weverling GJ; Bayat B; Custers JH; Dubois MC; Cohen J; Goudsmit J; Heppner DG
    Infect Immun; 2007 May; 75(5):2283-90. PubMed ID: 17307942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates.
    Capone S; Reyes-Sandoval A; Naddeo M; Siani L; Ammendola V; Rollier CS; Nicosia A; Colloca S; Cortese R; Folgori A; Hill AV
    Vaccine; 2010 Dec; 29(2):256-65. PubMed ID: 21029806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine.
    Ockenhouse CF; Angov E; Kester KE; Diggs C; Soisson L; Cummings JF; Stewart AV; Palmer DR; Mahajan B; Krzych U; Tornieporth N; Delchambre M; Vanhandenhove M; Ofori-Anyinam O; Cohen J; Lyon JA; Heppner DG;
    Vaccine; 2006 Apr; 24(15):3009-17. PubMed ID: 16356603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alternating vector immunizations encoding pre-erythrocytic malaria antigens enhance memory responses in a malaria endemic area.
    Bejon P; Kai OK; Mwacharo J; Keating S; Lang T; Gilbert SC; Peshu N; Marsh K; Hill AV
    Eur J Immunol; 2006 Aug; 36(8):2264-72. PubMed ID: 16856208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa.
    Sirima SB; Nébié I; Ouédraogo A; Tiono AB; Konaté AT; Gansané A; Dermé AI; Diarra A; Ouédraogo A; Soulama I; Cuzzin-Ouattara N; Cousens S; Leroy O
    Vaccine; 2007 Mar; 25(14):2723-32. PubMed ID: 17280744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial.
    Hermsen CC; Verhage DF; Telgt DS; Teelen K; Bousema JT; Roestenberg M; Bolad A; Berzins K; Corradin G; Leroy O; Theisen M; Sauerwein RW
    Vaccine; 2007 Apr; 25(15):2930-40. PubMed ID: 16914240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV; Biswas S; Pillai CR; Saxena RK
    Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants.
    Bliss CM; Drammeh A; Bowyer G; Sanou GS; Jagne YJ; Ouedraogo O; Edwards NJ; Tarama C; Ouedraogo N; Ouedraogo M; Njie-Jobe J; Diarra A; Afolabi MO; Tiono AB; Yaro JB; Adetifa UJ; Hodgson SH; Anagnostou NA; Roberts R; Duncan CJ; Cortese R; Viebig NK; Leroy O; Lawrie AM; Flanagan KL; Kampmann B; Imoukhuede EB; Sirima SB; Bojang K; Hill AV; Nébié I; Ewer KJ
    Mol Ther; 2017 Feb; 25(2):547-559. PubMed ID: 28153101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.
    Hodgson SH; Ewer KJ; Bliss CM; Edwards NJ; Rampling T; Anagnostou NA; de Barra E; Havelock T; Bowyer G; Poulton ID; de Cassan S; Longley R; Illingworth JJ; Douglas AD; Mange PB; Collins KA; Roberts R; Gerry S; Berrie E; Moyle S; Colloca S; Cortese R; Sinden RE; Gilbert SC; Bejon P; Lawrie AM; Nicosia A; Faust SN; Hill AV
    J Infect Dis; 2015 Apr; 211(7):1076-86. PubMed ID: 25336730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasmodium: mammalian codon optimization of malaria plasmid DNA vaccines enhances antibody responses but not T cell responses nor protective immunity.
    Dobaño C; Sedegah M; Rogers WO; Kumar S; Zheng H; Hoffman SL; Doolan DL
    Exp Parasitol; 2009 Jun; 122(2):112-23. PubMed ID: 19249301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers.
    Webster DP; Dunachie S; McConkey S; Poulton I; Moore AC; Walther M; Laidlaw SM; Peto T; Skinner MA; Gilbert SC; Hill AV
    Vaccine; 2006 Apr; 24(15):3026-34. PubMed ID: 16488059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein.
    Walther M; Thompson FM; Dunachie S; Keating S; Todryk S; Berthoud T; Andrews L; Andersen RF; Moore A; Gilbert SC; Poulton I; Dubovsky F; Tierney E; Correa S; Huntcooke A; Butcher G; Williams J; Sinden RE; Hill AV
    Infect Immun; 2006 May; 74(5):2706-16. PubMed ID: 16622207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The dog that did not bark: malaria vaccines without antibodies.
    Heppner DG; Schwenk RJ; Arnot D; Sauerwein RW; Luty AJ
    Trends Parasitol; 2007 Jul; 23(7):293-6. PubMed ID: 17512252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Contribution of influenza immunity and virosomal-formulated synthetic peptide to cellular immune responses in a phase I subunit malaria vaccine trial.
    Peduzzi E; Westerfeld N; Zurbriggen R; Pluschke G; Daubenberger CA
    Clin Immunol; 2008 May; 127(2):188-97. PubMed ID: 18337175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of cellular and humoral responses to recombinant protein and synthetic peptides of exon2 region of Plasmodium falciparum erythrocyte membrane protein1 (PfEMP1) among malaria patients from an endemic region.
    Das P; Grewal JS; Mahajan B; Chauhan VS
    Parasitol Int; 2007 Mar; 56(1):51-9. PubMed ID: 17258500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine.
    Porter DW; Thompson FM; Berthoud TK; Hutchings CL; Andrews L; Biswas S; Poulton I; Prieur E; Correa S; Rowland R; Lang T; Williams J; Gilbert SC; Sinden RE; Todryk S; Hill AV
    Vaccine; 2011 Oct; 29(43):7514-22. PubMed ID: 21501642
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of adjuvant on reactogenicity and long-term immunogenicity of the malaria Vaccine ICC-1132 in macaques.
    Langermans JA; Schmidt A; Vervenne RA; Birkett AJ; Calvo-Calle JM; Hensmann M; Thornton GB; Dubovsky F; Weiler H; Nardin E; Thomas AW
    Vaccine; 2005 Sep; 23(41):4935-43. PubMed ID: 15998554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial.
    de Graaf H; Payne RO; Taylor I; Miura K; Long CA; Elias SC; Zaric M; Minassian AM; Silk SE; Li L; Poulton ID; Baker M; Draper SJ; Gbesemete D; Brendish NJ; Martins F; Marini A; Mekhaiel D; Edwards NJ; Roberts R; Vekemans J; Moyle S; Faust SN; Berrie E; Lawrie AM; Hill F; Hill AVS; Biswas S
    Front Immunol; 2021; 12():694759. PubMed ID: 34335606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in The Gambia.
    Pinder M; Reece WH; Plebanski M; Akinwunmi P; Flanagan KL; Lee EA; Doherty T; Milligan P; Jaye A; Tornieporth N; Ballou R; McAdam KP; Cohen J; Hill AV
    Clin Exp Immunol; 2004 Feb; 135(2):286-93. PubMed ID: 14738458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS.
    Dunachie SJ; Walther M; Vuola JM; Webster DP; Keating SM; Berthoud T; Andrews L; Bejon P; Poulton I; Butcher G; Watkins K; Sinden RE; Leach A; Moris P; Tornieporth N; Schneider J; Dubovsky F; Tierney E; Williams J; Heppner DG; Gilbert SC; Cohen J; Hill AV
    Vaccine; 2006 Apr; 24(15):2850-9. PubMed ID: 16434127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.